Business Description
CareDx Inc
NAICS : 325413
SIC : 8071
ISIN : US14167L1035
Share Class Description:
CDNA: Ordinary SharesTotal Employee Number:
765Description
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 19.41 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 1.88 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 14.73 | |||||
Beneish M-Score | -3.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.7 | |||||
3-Year EBITDA Growth Rate | 57.7 | |||||
3-Year Book Growth Rate | -9.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 35.06 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.49 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.74 | |||||
9-Day RSI | 63.73 | |||||
14-Day RSI | 66.54 | |||||
3-1 Month Momentum % | 71.71 | |||||
6-1 Month Momentum % | 92.94 | |||||
12-1 Month Momentum % | 186.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.58 | |||||
Quick Ratio | 4.51 | |||||
Cash Ratio | 3.99 | |||||
Days Inventory | 63.02 | |||||
Days Sales Outstanding | 37.74 | |||||
Days Payable | 27.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.7 | |||||
Shareholder Yield % | 0.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.58 | |||||
Operating Margin % | -0.92 | |||||
Net Margin % | 24.23 | |||||
EBITDA Margin % | 2.24 | |||||
FCF Margin % | 18.34 | |||||
OCF Margin % | 20.45 | |||||
ROE % | 33.02 | |||||
ROA % | 24.85 | |||||
ROIC % | -2.25 | |||||
3-Year ROIIC % | 1927.57 | |||||
ROC (Joel Greenblatt) % | -6.56 | |||||
ROCE % | -1.19 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.33 | |||||
Forward PE Ratio | 42.82 | |||||
PE Ratio without NRI | 92.06 | |||||
Price-to-Owner-Earnings | 17.52 | |||||
PEG Ratio | 24.88 | |||||
PS Ratio | 5.84 | |||||
PB Ratio | 6.09 | |||||
Price-to-Tangible-Book | 6.98 | |||||
Price-to-Free-Cash-Flow | 31.76 | |||||
Price-to-Operating-Cash-Flow | 28.5 | |||||
EV-to-EBIT | -531.95 | |||||
EV-to-EBITDA | 219.79 | |||||
EV-to-Revenue | 4.91 | |||||
EV-to-Forward-Revenue | 4.25 | |||||
EV-to-FCF | 26.78 | |||||
Price-to-GF-Value | 2 | |||||
Price-to-Projected-FCF | 7.62 | |||||
Price-to-Median-PS-Value | 1.57 | |||||
Price-to-Graham-Number | 5.35 | |||||
| Price-to-Net-Current-Asset-Value | 8.07 | |||||
| Price-to-Net-Cash | 9.75 | |||||
Earnings Yield (Greenblatt) % | -0.19 | |||||
FCF Yield % | 3.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CDNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CareDx Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 458.089 | ||
| EPS (TTM) ($) | 2.07 | ||
| Beta | 3.9769 | ||
| 3-Year Sharpe Ratio | 0.86 | ||
| 3-Year Sortino Ratio | 1.79 | ||
| Volatility % | 56.88 | ||
| 14-Day RSI | 66.54 | ||
| 14-Day ATR ($) | 2.145551 | ||
| 20-Day SMA ($) | 45.0695 | ||
| 12-1 Month Momentum % | 186.35 | ||
| 52-Week Range ($) | 12.37 - 50.519 | ||
| Shares Outstanding (Mil) | 51.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CareDx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CareDx Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-25 | In 184 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 184 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 183 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 71 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | 35.41 (-1.01%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 35.41 (-1.01%) | ||
| General meeting for 2026 | 2026-06-11 10:00 | 23.46 (+3.76%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 13:20 | 22.25 (-3.93%) | ||
| Guidance call for 2026 | 2026-06-03 17:30 | 22.07 (-1.47%) |
Show
Entries
CareDx Inc Frequently Asked Questions
What is CareDx Inc(CDNA)'s stock price today?
The current price of CDNA is $50.36. The 52 week high of CDNA is $50.52 and 52 week low is $12.37.
When is next earnings date of CareDx Inc(CDNA)?
The next earnings date of CareDx Inc(CDNA) is 2026-11-04 Est..
Does CareDx Inc(CDNA) pay dividends? If so, how much?
CareDx Inc(CDNA) does not pay dividend.
Guru Commentaries on NAS:CDNA
Baron Discovery Fund
Bullish
2026 Q1
What the manager wrote
We thought that at their lowest levels of $11 to $12 last summer, CareDx shares were pricing in a worst-case scenario, and we meaningfully increased our position at those levels. Recently, shares have outperformed and are trading in the high-$20s as investors better understood that the LCD process is a dialogue between the CMS and key stakeholders and that the CMS may come to better appreciate recent clinical data. We expect the LCD to be finalized very soon. Further, in the second quarter of 2026, CareDx announced a very solid 1Q26 result with revenues up 39% year over year and testing volumes up 17% year over year. The company also announced financially and strategically attractive deals to divest its lab products business and acquire Naveris, marking the company's entrance into the head and neck cancer testing market.
Press Release
Articles on CareDx Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers